Payment overview · 2025
General Payments
$243.48
12 reported records · 5 companies
Healthcare provider profile · identity verified
Jacqueline Cain, DO
Allopathic & Osteopathic Physicians|Internal Medicine · KINGSTON, PA · NPI 1891708533
Verified facts
What the public records show
CMS Open Payments records show Jacqueline Cain, DO received $243.48 in general payments during 2025 across 12 reported records.
ABBVIE INC. accounted for 31.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $75.78 | 31.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.71 | 22.1% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $48.81 | 20.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.87 | 19.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.31 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $243.48 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $75.78 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $53.71 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $53.71 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $53.71 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $48.81 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
142 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
137 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 582 | 131 |
| Lisinopril | Lisinopril | 437 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 402 | 96 |
| Atorvastatin Calcium | Atorvastatin Calcium | 399 | 96 |
| Omeprazole | Omeprazole | 293 | 56 |
| Furosemide | Furosemide | 264 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 242 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 202 | 40 |
| Gabapentin | Gabapentin | 198 | 41 |
| Potassium Chloride | Potassium Chloride | 195 | 43 |
| Alprazolam | Alprazolam | 194 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 191 | 50 |
| Losartan Potassium | Losartan Potassium | 190 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 174 | 35 |
| Prednisone | Prednisone | 172 | 100 |
| Valsartan | Valsartan | 171 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 169 | 32 |
| Metformin Hcl | Metformin Hcl | 161 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 159 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 150 | 33 |
| Simvastatin | Simvastatin | 146 | 31 |
| Synthroid | Levothyroxine Sodium | 142 | 29 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 138 | 31 |
| Eliquis | Apixaban | 137 | 24 |
| Metformin Hcl Er | Metformin Hcl | 135 | 31 |
| Clonazepam | Clonazepam | 131 | 25 |
| Carvedilol | Carvedilol | 121 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 28 |
| Glimepiride | Glimepiride | 88 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 88 | 16 |
| Allopurinol | Allopurinol | 85 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 81 | 16 |
| Jardiance | Empagliflozin | 79 | 14 |
| Warfarin Sodium | Warfarin Sodium | 79 | 13 |
| Montelukast Sodium | Montelukast Sodium | 76 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 15 |
| Trazodone Hcl | Trazodone Hcl | 73 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 14 |
| Ibuprofen | Ibuprofen | 69 | 17 |
| Famotidine | Famotidine | 68 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 65 | 14 |
| Sertraline Hcl | Sertraline Hcl | 63 | 15 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 60 | 12 |
| Labetalol Hcl | Labetalol Hcl | 59 | 15 |
| Lorazepam | Lorazepam | 57 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 15 |
| Tramadol Hcl | Tramadol Hcl | 54 | suppressed |
| Meloxicam | Meloxicam | 53 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 11 |
| Amoxicillin | Amoxicillin | 49 | 25 |
| Bupropion Xl | Bupropion Hcl | 49 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 48 | suppressed |
| Azithromycin | Azithromycin | 48 | 42 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | suppressed |
| Pregabalin | Pregabalin | 46 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 44 | 11 |
| Atenolol | Atenolol | 43 | 12 |
| Diazepam | Diazepam | 42 | suppressed |
| Torsemide | Torsemide | 42 | suppressed |
| Verapamil Er | Verapamil Hcl | 40 | suppressed |
| Ozempic | Semaglutide | 39 | suppressed |
| Baclofen | Baclofen | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 20 |
| Cefuroxime | Cefuroxime Axetil | 37 | 32 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Irbesartan | Irbesartan | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Nystatin | Nystatin | 32 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 31 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Metolazone | Metolazone | 28 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 16 |
| Finasteride | Finasteride | 23 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Carbamazepine Er | Carbamazepine | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | 15 |
| Folic Acid | Folic Acid | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Nyamyc | Nystatin | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 13 |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 11 |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Nateglinide | Nateglinide | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Nadolol | Nadolol | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Azathioprine | Azathioprine | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Vyzulta | Latanoprostene Bunod | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Clarithromycin | Clarithromycin | 11 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $243.48 · 12 records | ABBVIE INC. | ABRYSVO, COMIRNATY, FREESTYLE LIBRE 3, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error